Felix A Kruger
Overview
Explore the profile of Felix A Kruger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1083
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hingorani A, Kuan V, Finan C, Kruger F, Gaulton A, Chopade S, et al.
Sci Rep
. 2019 Dec;
9(1):18911.
PMID: 31827124
Lack of efficacy in the intended disease indication is the major cause of clinical phase drug development failure. Explanations could include the poor external validity of pre-clinical (cell, tissue, and...
2.
Moya-Garcia A, Adeyelu T, Kruger F, Dawson N, Lees J, Overington J, et al.
Sci Rep
. 2017 Sep;
7(1):10102.
PMID: 28860623
Protein domains mediate drug-protein interactions and this principle can guide the design of multi-target drugs i.e. polypharmacology. In this study, we associate multi-target drugs with CATH functional families through the...
3.
Finan C, Gaulton A, Kruger F, Lumbers R, Shah T, Engmann J, et al.
Sci Transl Med
. 2017 Mar;
9(383).
PMID: 28356508
Target identification (determining the correct drug targets for a disease) and target validation (demonstrating an effect of target perturbation on disease biomarkers and disease end points) are important steps in...
4.
White J, Sofat R, Hemani G, Shah T, Engmann J, Dale C, et al.
Lancet Diabetes Endocrinol
. 2016 Jan;
4(4):327-36.
PMID: 26781229
Background: Increased circulating plasma urate concentration is associated with an increased risk of coronary heart disease, but the extent of any causative effect of urate on risk of coronary heart...
5.
Kruger F, Gaulton A, Nowotka M, Overington J
Bioinformatics
. 2014 Oct;
31(5):776-8.
PMID: 25348214
Unlabelled: PPDMs is a resource that maps small molecule bioactivities to protein domains from the Pfam-A collection of protein families. Small molecule bioactivities mapped to protein domains add important precision...
6.
Bento A, Gaulton A, Hersey A, Bellis L, Chambers J, Davies M, et al.
Nucleic Acids Res
. 2013 Nov;
42(Database issue):D1083-90.
PMID: 24214965
ChEMBL is an open large-scale bioactivity database (https://www.ebi.ac.uk/chembl), previously described in the 2012 Nucleic Acids Research Database Issue. Since then, a variety of new data sources and improvements in functionality...
7.
Kruger F, Rostom R, Overington J
BMC Bioinformatics
. 2013 Jan;
13 Suppl 17:S11.
PMID: 23282026
Background: Large-scale bioactivity/SAR Open Data has recently become available, and this has allowed new analyses and approaches to be developed to help address the productivity and translational gaps of current...
8.
Kruger F, Overington J
PLoS Comput Biol
. 2012 Jan;
8(1):e1002333.
PMID: 22253582
We report on the integration of pharmacological data and homology information for a large scale analysis of small molecule binding to related targets. Differences in small molecule binding have been...
9.
Bellis L, Akhtar R, Al-Lazikani B, Atkinson F, Bento A, Chambers J, et al.
Biochem Soc Trans
. 2011 Sep;
39(5):1365-70.
PMID: 21936816
The challenge of translating the huge amount of genomic and biochemical data into new drugs is a costly and challenging task. Historically, there has been comparatively little focus on linking...